brazikumab
Selected indexed studies
- IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. (Nat Rev Gastroenterol Hepatol, 2023) [PMID:37069321]
- Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? (Ann Rheum Dis, 2018) [PMID:28765121]
- Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease. (BMC Gastroenterol, 2023) [PMID:38124112]
_Worker-drafted node — pending editorial review._
Connections
brazikumab is a side effect of
Sources
- IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. (2023) pubmed
- Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? (2018) pubmed
- Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease. (2023) pubmed
- Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab. (2023) pubmed
- Blockade of IL-23: What is in the Pipeline? (2022) pubmed
- The Role of IL-23 Inhibitors in Crohn's Disease. (2023) pubmed
- Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. (2017) pubmed
- Promising phase II biologics for future Crohn's disease therapy. (2023) pubmed
- Anti-interleukin-23 agents for the treatment of ulcerative colitis. (2020) pubmed
- Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. (2019) pubmed